{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "G",
          "position": "209"
        },
        "variant_string_id": "SNCA A209G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The SNCA gene encodes alpha-synuclein, a protein that aggregates in Lewy bodies found in Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly states the disease mechanism of alpha-synuclein aggregation in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The authors used a functional assay to examine the effect of the A209G variant on alpha-synuclein aggregation in vitro.",
          "judgment": "Yes",
          "reasoning": "Alpha-synuclein aggregation assays are widely accepted as relevant to Parkinson's disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The authors used wild-type and null controls and performed experiments in triplicate.",
          "judgment": "Yes",
          "reasoning": "The presence of both wild-type and null controls and the use of triplicates suggests a valid assay setup.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "No known pathogenic or benign variants were used as controls.",
          "judgment": "No",
          "reasoning": "Variant controls would have strengthened the evidence but are not required for this type of assay.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A209G variant in SNCA showed increased alpha-synuclein aggregation in vitro using a valid assay setup, suggesting a potential pathogenic role in Parkinson's disease. However, the lack of variant controls limits the evidence strength to PS3_supporting."
    }
  ]
}